Date: 2012-09-13
Type of information:
phase: 1
Announcement: dosing of the first patient
Company: Zealand Pharma (Denmark)
Product: ZP2929
Action
mechanism: ZP2929 is a highly potent, dual acting agonist peptide that acts on both GLP-1 and glucagon receptors. The basis for the dual agonist concept that resulted in ZP2929 is the naturally occurring peptide hormone called oxyntomodulin. Oxyntomodulin is produced by the small intestine after meals, and is believed to exert its biological effects by activating both the GLP-1 receptor and the glucagon receptor. In humans, this hormone is believed to have multiple beneficial effects on metabolism and obesity, improving glucose tolerance and causing substantial weight loss.
In validated pre-clinical models of diabetes (db/db mice) and obesity (Diet Induced Obese (DIO) mice), ZP2929 has been shown to significantly improve glycemic control (HbA1c) and induce a sustained weight loss for at least 6 weeks.
Disease: diabetes
Therapeutic area: Metabolic diseases
Country: USA
Trial
details: The clinical development of ZP2929 will start with a randomized, double-blind, first in human study to evalCuate the safety and tolerability of single ascending daily doses of ZP2929 in healthy subjects. The study will be conducted in the United States under an Investigational New Drug (IND) application with the FDA.
Latest
news: Zealand Pharma, a Danish biotechnology company dedicated to the discovery and development of innovative peptide drugs, has announced that the first participant has been dosed in the first Phase I clinical study of ZP2929.
ZP2929 is a dual acting glucagon/GLP-1 peptide agonists, invented by Zealand Pharma and with global rights out-licensed to Boehringer Ingelheim as part of a global license and research collaboration between the two companies on dual acting glucagon/GLP-1 agonists for the treatment of patients with Type 2 diabetes and/or patients with obesity. Under the terms of the collaboration, Boehringer Ingelheim will finance all clinical development activities of ZP2929, including Phase I (See http://biopharmanalyses.fr/agreements/?pageid=50). Zealand Pharma will be responsible for conducting the first Phase I study, and Boehringer Ingelheim will be responsible for the clinical development thereafter.
The advancement of ZP2929 into clinical development triggers a milestone payment to Zealand Pharma from Boehringer Ingelheim.
